cyrilzakka/clinical-trials huggingface dataset:
Efficacy of Arthrocentesis by Injection of Ringer With or Without Corticosteroid in Treatment of Internal Derangement

The study aims to evaluate effectiveness of ringer injection with or without corticosteroid during arthrocentesis of the temporomandibular joint in the treatment of internal derangement of the temporomandibular joint (TMJ).

This prospective clinical study was approved by Local ethical committee and written informed consent will be obtained before the trial starts. Criteria for selection of the patients was based on history and clinical findings characteristic of internal derangement. All these patients were initially treated with NSAIDS for 1 week and occlusal splints for 1 month had failed to respond to these conservative treatments. The patients with systemic problems which affect bone and joints,psychological problems ,history of maxillofacial fractures and orthognathic surgery were excluded from the study. A total of 60 patients with TMJ internal derangement with failed conservative management, were subjected to TMJ arthrocentesis. All arthrocentesis were performed by the same maxillofacial surgeon. Subjects were randomly allocated into two groups (30 cases in each group). Subjects in the group 1 received irrigation with Ringer solution and in the group 2 ,subjects underwent irrigation with Ringer solution with corticosteroid (Dexamethasone ) .Two examiners evaluated Temporomandibular disorder's signs ( mouth opening,click , crepitus and pain) before, one month and 6 months after arthrocentesis.

Eligibility Criteria:
Inclusion Criteria:

* Patients with clinical findings characteristic of internal derangement(clicking and joint pain lasting for more than 6 months) unilaterally or bilaterally and history of previous conservative drug therapy (NSAIDs and Muscle relaxant ),splint therapy and physiotherapy without improvement.
* Patients of both sexes between 15 to 80 year's old
* Patients who are willing for evaluation in 1 and 6 months after arthrocentesis
* Patients who are provided written consent form

Exclusion Criteria:

* Patient had systemic problems which affect bone and joints disease
* Patient with psychological problems
* Patient with history of maxillofacial fractures and orthognathic
* Patients who can not continue the study for private or social reasons
Liposomal Bupivacaine in Total Knee Arthroplasty

Pain management after total knee arthroplasty is essential for optimized clinical outcomes and higher satisfaction. Exparel (Pacira Pharmaceuticals, Parsippany, New Jersey, USA) is a long-acting Bupivacaine extended release liposome compound that is injected peri-articularly or as regional block. The purpose of this study was to compare the analgesic efficacy of single administration of Exparel for local peri-articular infiltration versus adductor canal regional block.

Multimodal pain approach is now an accepted standard of care to improve pain, enable earlier mobilization and faster recovery, decreased length of stay, and reduce opioid consumption and related side effects. The multimodal approach includes peri-operative oral and IV analgesics, local periarticular injections (PAI), and/or regional blocks such as femoral nerve blocks nerve or subsartorial saphenous nerve (adductor canal) blocks. Extended release bupivacaine (Exparel - Pacira Pharmaceuticals, Parsippany, NJ, USA) in liposomal form was developed for longer lasting post-operative analgesia. There are limited studies analyzing its efficacy of single injection liposomal bupivacaine in adductor canal block in total knee arthroplasty. The investigators hypothesized that a single adductor canal regional block injection would provide similar pain relief as peri-articular infiltration of Exparel.

Eligibility Criteria:
Inclusion Criteria:

* primary knee osteoarthritis undergoing unilateral knee replacement

Exclusion Criteria:

* hypersensitivity and/or allergies to local anesthetics or previous knee surgery
CGA-TAVI Registry to Evaluate the Predictive Value of a CGA in Predicting TAVI Outcomes

Registry study to evaluate the predictive value of a comprehensive geriatric assessment with regard to the outcome of a transcatheter aortic valve Implantation.

It will be evaluated which parts of the comprehensive geriatric assessment (CGA) are best suited to predict the therapeutic success of a heart valve Implantation in elderly ( \> 80 years) Patient. Possible participants are all Patient of 80 years or above for whom the implantation of a Edwards Sapien XT aortic valve is planned

Transcatheter Aortic Valve Implantation Registry with Comprehensive Geriatric Assessment

Eligibility Criteria:
Inclusion Criteria:

* Scheduled TAVI using Edwards SAPIEN XT Transcatheter Heart Valve
* Compliance with the indications of the instructions for use
* Age of at least 80 years
* Written informed consent

Exclusion Criteria:

* Presence of contraindications as to the Instructions for Use
* No possibility for a follow-up
Drug Use Investigation for Toviaz

The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.


Eligibility Criteria:
Inclusion Criteria:

* Patients prescribed fesoterodine (Toviaz).

Exclusion Criteria:

* There are no exclustion criteria
Comparison of Fasting Blood Glucose Measurements From Fingertip and Intravenous on Patient Satisfaction in Patients With Diabetes Mellitus

The study was designed as a randomized controlled experimental study in order to compare the fasting blood glucose values measured by puncturing the fingertips and using the intravenous route of patients diagnosed with diabetes mellitus, and to determine the effect on patient satisfaction. The blood glucose measurement via the intravenous catheter has an effect on increasing the comfort of the patient compared to the fingertip measurement. It is thought that information can be provided to increase patient satisfaction.


Eligibility Criteria:
Inclusion Criteria:

* 18 years and older
* No advanced hearing and vision problems
* Able to speak and understand Turkish
* Easy to communicate
* literate
* Agreeing to participate in the research voluntarily
* Patients who are hospitalized
* Regular finger blood sugar monitoring,
* Patients with an intravenous vascular access date within the first 24 hours
* Patients who had been diagnosed with Type 2 Diabetes Mellitus for at least one year were.

Exclusion Criteria:

* Those who are treated with sedative drugs
* Patients using antipsychotic medication
* Patients with continuous drug infusion through the intravenous line
* Patients whose intravenous vascular access date has passed 24 hours
* Patients in unconscious, confused, apathetic state
Electromagnetic Field Versus Diclofenac Drugs on Primary Dysmenorrhea

Electromagnetic field versus diclofenac drugs on primary dysmenorrhea: Arandomized controlled trial in the Egyptian women

Background: Primary dysmenorrhea is one of the most common complaints of women and is also the most common gynecological problem worldwide. These cramps are recurrent and 90% adolescent girls and about 50% women suffer from it. Purpose of the study: to determine which is more effective in alleviating primary dysmenorrhea; pulsed electromagnetic field or diclofenac drugs. Methodology: The study was a randomized, double-blinded trial, fifty adult females participated in this study, were divided randomly into two groups equal in numbers: group (A) received pulsed electromagnetic field applied on pelvic region, 3 times per week for 3 months, 20 minutes per day and group (B) received diclofenac tablets, 50 mg only with onset of menstrual pain. All participants in both groups (A and B) were assessed pre- and post-treatment through measuring progesterone level in the blood, assessment of pain using visual analogue scale and physical as well as psychological symptoms by using menstrual symptom questionnaire.

Eligibility Criteria:
Inclusion Criteria:

-regular menstrual cycle 21-35 days lasting 3-7 days

Exclusion Criteria:

* Irregulars or infrequent menstrual cycles, Pacemaker, Myasthenia gravis, hyperthyroidism, active tuberculosis and psychosis
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks compared to treatment with sofosbuvir (SOF) plus ribavirin (RBV) for 12 weeks in participants with chronic genotype 2 hepatitis C virus (HCV) infection.


Eligibility Criteria:
Inclusion Criteria:

* Willing and able to provide written informed consent
* HCV RNA ≥ 10\^4 IU/mL
* HCV genotype 2
* Chronic HCV infection (≥ 6 months)
* Females of childbearing potential must have a negative serum pregnancy test
* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
* Must be of generally good health, with the exception of chronic HCV infection, as determined by the investigator.

Exclusion Criteria:

* Current or prior history of clinically-significant illness (other than HCV that may interfere with treatment, assessment or compliance with the protocol;
* Screening electrocardiogram (ECG) with clinically significant abnormalities
* Laboratory results outside of acceptable ranges at Screening
* Pregnant or nursing female or male with pregnant female partner
* Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, cholangitis)
* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
Feasibility of Imaging in the Treatment of Patients With Advanced Head and Neck Cancer

The purpose of this study is to obtain preliminary information on the potential of 99m Tc-EC-DG SPECT imaging to distinguish cancer from non cancer.


Eligibility Criteria:
Inclusion Criteria:

* Treatment naive patients with histologically proven cancer of the head and neck
* T4 primary tumor (all sites), N2 or N3 locoregional disease (all sites)
* At least one measurable site of disease
* At least 18 years of age
* Karnofsky performance status \> or = 70% or ECOG \<2
* Able to tolerate SPECT/CT imaging
* Adequate bone marrow function
* Adequate liver function
* Adequate renal function
* Written consent from patients
* Female patients of childbearing potential must have a negative pregnancy test within 0-7 days prior to the first SPECT study

Exclusion Criteria:

* Diabetics with insulin dependence or blood sugar levels \>200 mg/dL prior to imaging
* Patient weight above the SPECT/CT table weight limit
* Pregnant and/or lactating female
* Unequivocal demonstration of metastatic disease
* Patients unwilling to or unable to comply with protocol
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

To explore the safety, tolerability and clinical effects of decitabine combined with R±DHAP for patients with replase and refractory Diffuse Large B cell lymphoma.

This is a randomized,controlled,prospective,open,multi-center clinical trial,amied to evaluate the safety, tolerability,and efficacy of decitabine combined with R±DHAP in replase and refractory Diffuse Large B cell lymphoma.A total of 60 patients are planned to be enrolled into the study.Patients with diagnosis of replase and refractory Diffuse Large B cell lymphoma will be into two groups,and be treated with decitabine pluse R±DHAP or only R±DHAP,respectively.The primary end points are objective responder rate(ORR) and time to progression(TTP) and the secondary end points include overall survival(OS) and progression free survival(PFS).

Eligibility Criteria:
Inclusion Criteria:

* age:14-65 years;ECOG rate≤2;expected survival≥3 months
* patients with Diffuse Large B cell lymphoma diagnoesd by histopathology detection;
* patients ever received RCHOP or CHOP chemotherapy but did not receive DHAP
* patients never received radiotherapy
* patients with no chemotherapy contraindications:hemoglobin ≥ 90g/L,absoluate neutrophil count ≥1.5x109/L,blood platelet ≥100x109/L,ALT and AST ≤ 2-fold upper normal limit,serum bilirubin ≤1.5-fold upper normal limit,serum creatinine ≤1.5-fold upper normal limit,serum albumin ≥ 30g/L,normal serofibrinogen;
* at least one measurable nidus;
* no other severe diseases conflict with this project,cardiopulmonary function is basically normal
* the urine or blood pregnancy test of women in childbearing age must be negative in 7 days before follow-up visit;
* applicable for follow-up visit;
* no other antitumor adjoint therapy(including antitumor Chinese medicine,immunotherapy and biotherapy),but double phosphate anti-bone transfer therapy and other symptomatic treatment are acceptable;
* understanding this study and assigning informed consent.

Exclusion Criteria:

* rejecting providing blood preparation;
* allergic to drug in this study and with metabolic block;
* rejecting adopting reliable contraceptive method in pregnancy or lactation period;
* uncontrolled internal medicine disease(including uncontrolled diabetes,severe incompetence cardiac,lung,liver and pancreas）；
* with severe infection;
* with primary or secondary central nervous system tumor invasion;
* with immunotherapy or radiotherapy contraindication;
* ever suffered with malignant tumor;
* having peripheral nervous system disorder or dysphrenia;
* with no legal capacity,medical or ethical reasons affecting research proceeding;
* participating other clinical trials simultaneously;
* adopting other anti-tumor medicine excluding this research;
* the researchers considering it inappropriate to participate in the study.
Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

This study is designed to determine the safety of RSD1235 in patients with atrial fibrillation.


Eligibility Criteria:
Inclusion Criteria:

* Subject must have symptomatic AF
* Subject must have adequate anticoagulant therapy

Exclusion Criteria:

* Subject may not have Class IV congestive heart failure.
* Subject may not have uncorrected electrolyte imbalance.
Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss

Miscarriage occurs in about 1-2% of human pregnancies and is one of the common pregnancy problems before 12 weeks of pregnancy. Anatomical and chromosomal abnormalities, microbial factors and auto and alloimmune reactions have been speculated to attribute in recurrent miscarriage. Unexplained recurrent miscarriage (URM) is defined as three or more repeated abortions, probably caused by maternal immunological rejection . Given that maternal immune system encounters semi-allogeneic fetus, pregnancy outcome is associated with the interaction between maternal immune system and immuno-regulatory capability of the fetus. Effectiveness of treatment approaches in RM patients has been controversial and remained to be discovered. Immunomodulatory agents such as corticosteroids and allogeneic lymphocyte immunization showed variable success rates in RM patients. Therapeutic effects of IVIG in unexplained RM is controversial and most positive results were obtained from the trials in RM women with cellular immune abnormalities, such as increased NK cell level and/or cytotoxicity, and T cell abnormalities. Previous studies have shown that the incidence of genetic abnormalities in children who have received immunosuppressive drugs such as IVIg like normal people and normal society. In this study we used IVIg at the time of positive pregnancy,400 mg/kg IVIG was administered intravenously. Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation to suppress the immune system in patients with immunological causes of RPL and the results will be compared with a control group that did not receive any type of drug.


Eligibility Criteria:
Inclusion Criteria:

* Enrolled patients will experience at least 3 times recurrent pregnancy loss.
* Patients dont have history of any type of immunotherapy.
* Patients must have abnormal NK cell or NK cell cytotoxicity or Th1/Th2 ratio

Exclusion Criteria:

- Our criteria for exclusion of patients from the study include the following:

* Patients or their spouse has abnormal karyotype or chromosomal and genetically disorders.
* Patients who have bleeding problems.
* Patients who have chronic disorders those are forced to use the specific drug.
* Patients who have positive test for HIV, HCV or HBV infection.
* Patients who have a history of asthma and allergies.
* Patients who have uterus abnormalities.
The Effectiveness of an E-Intervention on Health Behavior Promotion in Chinese University Students

Through the internet and mobile phone SMS technology, and by using the Health Action Process Approach model as a theoretical backdrop, this 8-week theory-based intervention study aimed at developing a healthy lifestyle by supporting physical activity (PA) and a healthy dietary for Chinese university students. The investigators would examine whether the two intervention groups improve the participants' motivation for PA and healthy diets in comparison to the control group; whether, with the help of an intervention program, students are able to increase the PA levels and healthy diet consumption, and whether there are different effects between the two intervention programs.

For the main study, the sample size was estimated by using G\*Power 3.1 software with MANOVA approach (repeated measure). For achieving small effect size of 0.15 (Lippke, Fleig, Wiedemann, \& Schwarzer, 2015), with a power (1-β) of 0.8 and alpha of 0.05, the total sample size was 306. Assuming a drop-out rate of approximately 30%, a total of 399 participants were required for the study evaluation.

The effects of the intervention were evaluated by performing several analyses of MANOVA and MANCOVA measured at three points in time (8-week apart pre-post measures, and four weeks follow-up; T1-T3).In addition, moderated multiple mediation analysis was performed (Independent variable: intervention; Moderators: stage; Dependent variable: behavioural and social-cognitive outcomes). Baseline characteristics of participants who dropped out were compared with participants who finished the intervention to examine whether drop out is at random or determined by specific characteristics.

Eligibility Criteria:
Inclusion Criteria:

* not professional athletes; not vegetarians
* no contraindication with respect to the physical activity or fruit and vegetable consumption.
* access to the Internet and a mobile phone.

Exclusion Criteria:

* have the restriction of physical mobility
* have fruit-vegetable related diseases such as diabetes or fruit allergies.
Investigation of the Effect of Orthosis Use for Control of Knee Hyperextension in Chronic Stroke Patients

The aim of this study is to examine the effect of using foot-ankle orthosis at different angles on hyperextension control in stroke patients.

The hypotheses of the study are:

Hypothesis 1:

Ho: The foot-ankle orthosis, which fixes the ankle at different angles (3 degrees of dorsiflexion - 5 degrees of dorsiflexion) in stroke patients, has no effect on the control of knee hyperextension.

H1: Foot-ankle orthosis, which fixes the ankle at different angles (3 degrees of dorsiflexion - 5 degrees of dorsiflexion) in stroke patients, has an effect on the control of knee hyperextension.


Eligibility Criteria:
Inclusion Criteria:

* Between the ages of 40 and 65
* Six months must have passed since the stroke.
* Ambulation regardless of the use of a walking aid (walker, cane, or tripod)
* Obtaining between 0 and 3 Modified Rankin Score points
* A score of 24 or higher on the Mini Mental Test is required to pass.
* Hyperextension during the stance phase of gait.
* Participating voluntarily in the study

Exclusion Criteria:

* Having a history of more than one stroke
* Dementia is known to exist
* Having a diagnosed orthopedic, mental, or neurological condition
* Having a circumstance that impedes communication
* Having a history of lower extremity and gait-related surgeries
The Effect of Matrix Rhythm Therapy in Patients With Chronic Neck Pain

Thirty individuals with chronic neck pain randomised into two groups. Group I (15 subjects) received a total of 10 sessions as 5 sessions a week.Hot pack to cervical and upper thoracic regions (20 minutes), conventional Transcutaneous Electrical Nerve Stimulation (TENS) (100 Hz for 40 μsec), therapeutic ultrasound (1 Megahertz (MHz) for 5 minutes) and conventional massage were applied. Five sessions of Matrix Rhythm Therapy (2., 5., 6., 8., 10. sessions of combined physiotherapy programme) was added at combined physiotherapy Group II. Matrix Rhythm Therapy was applied to cervical and thoracic regions using 10 Hz frequency for 30 minutes.

Pain intensity was measured using by a Visual Analogue Scale (VAS) measuring 10 cm. Muscle spasm in cervical region was assessed by using a VAS measuring 10 cm. Turkish version of Neck Disability Index (NDI) was used to assess the disability caused by neck pain. Turkish version of Beck Depression Inventory was used to assess emotional status of participants.

The study included patients aged between 25-65 years who had neck pain for at least 3 months. Patients with radiculopathy who had motor findings, who underwent any operations due to neck problems, who had systemic, neurologic and psychiatric diseases, inflammatory or infectious diseases, history of malignity, congenital anomalies, who benefited from another therapy modality and the ones in whom physical therapy modalities could not be used due to contraindications (individuals with sensory disorders, who use cardiac pace maker) were excluded from the study.

A total of 36 individuals were randomly assigned into 2 groups. Randomization was allocated by numbered envelopes method. A total of 30 subjects (15 in Matrix Rhythm Therapy (MRT) group and 15 in CG) with neck pain due to mechanic causes like cervical discopathy, cervical arthrosis or myofascial pain syndrome were participated in this study.

All assessments were done by the same physiotherapist (FU) before therapy and at the end of treatment sessions. The physiotherapist who did the assessments did not know to which group the subjects were belonged. Another physiotherapist who was not informed about the results of the evaluation treated the patients.

Home-based exercise programs and recommendations were also given to patients. Matrix Rhythm Therapy is developed by Dr. Ulrich G. Randall at the university of Erlangen/Nuremberg. Longitudinal stroking, compression and spooning techniques are specific methods of MRT. Therapies of the patients were done by the physiotherapist who had certificate of MRT application.

Eligibility Criteria:
Inclusion Criteria:

* Having neck pain for at least 3 months

Exclusion Criteria:

* radiculopathy with motor findings
* undergoing surgical operation for neck pathologies
* having a systemic , neurologic, psychiatric diseases
* inflammatory or infectious diseases targeting this region
* physical therapy modalities could not be used due to contraindications (individuals with sensory disorders, who use cardiac pace maker)
* pregnancy
* malignancy